US equities |
NVDA $239.29 ▲+0.17% MU $1,047.22 ▼-1.57% SPCX $173.16 ▲+1.21% MRVL $286.33 ▲+5.56% AMD $649.68 ▲+2.84% INTC $113.26 ▼-2.52% SNDK $1,662.40 ▼-2.45% AVGO $377.52 ▲+4.14%
FinancialContent

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

78.04 -3.39 (-4.16%)
Delayed Quote Updated: 3:49 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗
The drugmaker is doing nearly everything else right. 
Via The Motley Fool
News headline image
Is Mirum Pharmaceuticals About to Soar in 2026? ↗
The future looks bright for this high-flying biotech stock. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage... 
Via PredictStreet
Topics Economy Initial Public Offering
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Via Chartmill
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗
Via Stocktwits
News headline image
3 Top Growth Stocks to Buy in the First Half of 2026 ↗
Don't wait too long to make a decision on these three stocks. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 ↗
Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗
Not all of these predictions may come true. But at least a few of them will likely do so. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now ↗
These predictions were easy. 
Via The Motley Fool
News headline image
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 ↗
Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on. 
Via The Motley Fool
Topics Earnings
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout. 
Via Chartmill
News headline image
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗
One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds. 
Via The Motley Fool
News headline image
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗
This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >